Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care

Study protocol for a randomised controlled trial

Anja Van Der Hout, Cornelia F. Van Uden-kraan, Birgit I. Witte, Veerle M. H. Coupé, Femke Jansen, C. René Leemans, Pim Cuijpers, L.V. van de Poll-Franse, Irma M. Verdonck-de Leeuw

Research output: Contribution to journalArticleScientificpeer-review

4 Downloads (Pure)

Abstract

Background:
Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.

Methods/design:
Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included. In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group. The primary outcome measure is patient activation. Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life. Furthermore, cost-utility outcomes will be assessed. Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial. Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up.

Discussion:
In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas. These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas
Original languageEnglish
Article number228
JournalTrials
Volume18
Issue number1
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Survivors
Neoplasms
Patient Participation
Head and Neck Neoplasms
Lymphoma
Maintenance
Physicians

Cite this

Van Der Hout, Anja ; Van Uden-kraan, Cornelia F. ; Witte, Birgit I. ; Coupé, Veerle M. H. ; Jansen, Femke ; Leemans, C. René ; Cuijpers, Pim ; van de Poll-Franse, L.V. ; Verdonck-de Leeuw, Irma M. / Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care : Study protocol for a randomised controlled trial. In: Trials. 2017 ; Vol. 18, No. 1.
@article{5705fac3f55e408ea55e9eac14517d4f,
title = "Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care: Study protocol for a randomised controlled trial",
abstract = "Background: Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.Methods/design: Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included. In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group. The primary outcome measure is patient activation. Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life. Furthermore, cost-utility outcomes will be assessed. Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial. Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up.Discussion: In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas. These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas",
author = "{Van Der Hout}, Anja and {Van Uden-kraan}, {Cornelia F.} and Witte, {Birgit I.} and Coup{\'e}, {Veerle M. H.} and Femke Jansen and Leemans, {C. Ren{\'e}} and Pim Cuijpers and {van de Poll-Franse}, L.V. and {Verdonck-de Leeuw}, {Irma M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1186/s13063-017-1952-1",
language = "English",
volume = "18",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care : Study protocol for a randomised controlled trial. / Van Der Hout, Anja; Van Uden-kraan, Cornelia F.; Witte, Birgit I.; Coupé, Veerle M. H.; Jansen, Femke; Leemans, C. René; Cuijpers, Pim; van de Poll-Franse, L.V.; Verdonck-de Leeuw, Irma M.

In: Trials, Vol. 18, No. 1, 228, 01.12.2017.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Efficacy, cost-utility and reach of an eHealth self-management application 'Oncokompas' that helps cancer survivors to obtain optimal supportive care

T2 - Study protocol for a randomised controlled trial

AU - Van Der Hout, Anja

AU - Van Uden-kraan, Cornelia F.

AU - Witte, Birgit I.

AU - Coupé, Veerle M. H.

AU - Jansen, Femke

AU - Leemans, C. René

AU - Cuijpers, Pim

AU - van de Poll-Franse, L.V.

AU - Verdonck-de Leeuw, Irma M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.Methods/design: Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included. In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group. The primary outcome measure is patient activation. Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life. Furthermore, cost-utility outcomes will be assessed. Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial. Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up.Discussion: In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas. These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas

AB - Background: Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment. Therefore, it is essential that they have access to optimal supportive care services. The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support. A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.Methods/design: Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included. In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group. The primary outcome measure is patient activation. Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life. Furthermore, cost-utility outcomes will be assessed. Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial. Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up.Discussion: In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas. These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas

U2 - 10.1186/s13063-017-1952-1

DO - 10.1186/s13063-017-1952-1

M3 - Article

VL - 18

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 228

ER -